Sparcl1/Hevin drives pathological pain through spinal cord astrocyte and NMDA receptor signaling.

dc.contributor.author

Chen, Gang

dc.contributor.author

Xu, Jing

dc.contributor.author

Luo, Hao

dc.contributor.author

Luo, Xin

dc.contributor.author

Singh, Sandeep K

dc.contributor.author

Ramirez, Juan J

dc.contributor.author

James, Michael L

dc.contributor.author

Mathew, Joseph P

dc.contributor.author

Berger, Miles

dc.contributor.author

Eroglu, Cagla

dc.contributor.author

Ji, Ru-Rong

dc.date.accessioned

2022-11-01T13:21:16Z

dc.date.available

2022-11-01T13:21:16Z

dc.date.issued

2022-10

dc.date.updated

2022-11-01T13:21:15Z

dc.description.abstract

Hevin/Sparcl1 is an astrocyte-secreted protein and regulates synapse formation. Here we show that astrocytic hevin signaling plays a critical role in maintaining chronic pain. Compared to wild-type mice, hevin-null mice exhibited normal mechanical and heat sensitivity but reduced inflammatory pain. Interestingly, hevin-null mice have faster recovery than wild-type mice from neuropathic pain after nerve injury. Intrathecal injection of wild-type hevin was sufficient to induce persistent mechanical allodynia in naïve mice. In hevin-null mice with nerve injury, AAV-mediated re-expression of hevin in GFAP-expressing spinal cord astrocytes could reinstate neuropathic pain. Mechanistically, hevin is crucial for spinal cord NMDA receptor (NMDAR) signaling. Hevin potentiated NMDA currents mediated by the GluN2B-containing NMDARs. Furthermore, intrathecal injection of a neutralizing antibody against hevin alleviated acute and persistent inflammatory pain, postoperative pain, and neuropathic pain. Secreted hevin was detected in mouse cerebrospinal fluid (CSF) and nerve injury significantly increased CSF hevin abundance. Finally, neurosurgery caused rapid and substantial increases in SPARCL1/HEVIN levels in human CSF. Collectively, our findings support a critical role of hevin and astrocytes in the maintenance of chronic pain. Neutralizing of secreted hevin with monoclonal antibody may provide a new therapeutic strategy for treating acute and chronic pain and NMDAR-medicated neurodegeneration.

dc.identifier

161028

dc.identifier.issn

2379-3708

dc.identifier.issn

2379-3708

dc.identifier.uri

https://hdl.handle.net/10161/26120

dc.language

eng

dc.publisher

American Society for Clinical Investigation

dc.relation.ispartof

JCI insight

dc.relation.isversionof

10.1172/jci.insight.161028

dc.subject

Neurological disorders

dc.subject

Neuroscience

dc.title

Sparcl1/Hevin drives pathological pain through spinal cord astrocyte and NMDA receptor signaling.

dc.type

Journal article

duke.contributor.orcid

James, Michael L|0000-0002-8715-5210

duke.contributor.orcid

Mathew, Joseph P|0000-0002-3815-4131

duke.contributor.orcid

Berger, Miles|0000-0002-2386-5061

duke.contributor.orcid

Eroglu, Cagla|0000-0002-7204-0218

duke.contributor.orcid

Ji, Ru-Rong|0000-0002-9355-3688

pubs.begin-page

e161028

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Anesthesiology

pubs.organisational-group

Anesthesiology, Cardiothoracic

pubs.organisational-group

Anesthesiology, Neuroanesthesia

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

University Institutes and Centers

pubs.organisational-group

Duke Institute for Brain Sciences

pubs.organisational-group

Neurology

pubs.organisational-group

Neurology, Neurocritical Care

pubs.organisational-group

Initiatives

pubs.organisational-group

Duke Science & Society

pubs.organisational-group

Duke Innovation & Entrepreneurship

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ru Rong SPARCL pain paper 2022.pdf
Size:
2.36 MB
Format:
Adobe Portable Document Format